AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in the field of migraine.
​
Additional eligibility requirements are listed below.
Terms & Conditions
Each applicant must acknowledges that they have read the official Terms and Conditions and they fully agrees and accept them.
Golden Ticket Benefits
Application requirements
AbbVie is looking for early-stage biotech companies that fit the following criteria:
-
Have primary business location in US, France or Germany​
-
Be an early stage-startup focused on developing novel therapeutic approaches for migraine that could include both central and peripheral mechanisms for treating acute migraine and migraine prevention.​
-
Related research areas in pain with potential application(s) to migraine will also be considered.
-
Excluded are devices, neuromodulation technologies and similar technologies.
-
For additional requirements refer to the Terms and Conditions document.
Therapeutic focus of this call for applications
Migraine
The Application Process
01
Submit applications by
November 21, 2025
02
A subset of applications will be identified as finalist by the contest judges by
Date TBC
03
Finalists will present their company & scientific concept at a virtual event
on Date TBC
04
One Golden Ticket will be awarded to one winner
Contact Us
If you have any questions about this Golden Ticket,
contact: global_goldenticket@abbvie.com
​
For any questions about BioLabs,
contact: goldenticket@biolabs.io
